AllianceBernstein
JUNO

AllianceBernstein’s Juno Therapeutics, Inc. JUNO Stock Holding History

AllianceBernstein’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-34,170
Closed -$1.56M – 3083
2017
Q4 		$1.56M Buy
34,170
+150
+0.4% +$7.48K ﹤0.01% 2024
2017
Q3 		$1.53M Sell
34,020
-400
-1% -$13.6K ﹤0.01% 2034
2017
Q2 		$1.03M Sell
34,420
-1,256
-4% -$31K ﹤0.01% 2278
2017
Q1 		$792K Sell
35,676
-150
-0.4% -$3.22K ﹤0.01% 2352
2016
Q4 		$675K Sell
35,826
-660
-2% -$16.1K ﹤0.01% 2447
2016
Q3 		$1.09M Sell
36,486
-250
-0.7% -$7.78K ﹤0.01% 2180
2016
Q2 		$1.41M Buy
36,736
+21,450
+140% +$890K ﹤0.01% 1996
2016
Q1 		$582K Buy
15,286
+20
+0.1% +$697 ﹤0.01% 2365
2015
Q4 		$671K Buy
15,266
+1,100
+8% +$54.6K ﹤0.01% 2332
2015
Q3 		$576K Sell
14,166
-13,160
-48% -$577K ﹤0.01% 2437
2015
Q2 		$1.46M Buy
27,326
+14,166
+108% +$752K ﹤0.01% 2055
2015
Q1 		$798K Sell
13,160
-306,361
-96% -$14.9M ﹤0.01% 2302
2014
Q4 		$16.7M Buy
+319,521
New +$14.3M 0.01% 752

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

AllianceBernstein's JUNO Position: Q1 2018 in Review

AllianceBernstein sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 34,170 shares — an estimated $1.56M sold.

AllianceBernstein first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $16.7M in Q4 2014. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • AllianceBernstein reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • AllianceBernstein sold 34,170 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1.56M.
  • AllianceBernstein first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • AllianceBernstein's Juno Therapeutics, Inc. position peaked at $16.7M in Q4 2014.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on AllianceBernstein's 13F filing for Q1 2018, filed 14 May 2018.